<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462303</url>
  </required_header>
  <id_info>
    <org_study_id>SheffieldHallamAquili2018</org_study_id>
    <nct_id>NCT03462303</nct_id>
  </id_info>
  <brief_title>Modulation of Cognitive Flexibility by Tyrosine Depletion and Transcranial Direct Current Stimulation</brief_title>
  <official_title>Modulation of Cognitive Flexibility by Tyrosine Depletion and Transcranial Direct Current Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Hallam University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheffield Hallam University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dorsolateral prefrontal cortex (dlPFC) and dopamine (DA) have been implicated in the
      control of cognitive flexibility. However, while a great deal of what it is know regarding a
      causative relationship between cognitive flexibility and its neuronal underpinning comes from
      animal studies, human data have largely been correlational (i.e. imaging investigations). In
      a recent study, the current research group examined whether putative increases in dopamine
      levels through tyrosine administration and blockage of these by cathodal (i.e. inhibitory)
      transcranial direct current stimulation (tDCS) of the dlPFC could be causally related to
      cognitive flexibility as measured by task switching and reversal learning.

      The next step involves finding a way of lowering dopamine concentrations while anodal (i.e.
      excitatory) stimulation of the dlPFC is applied and cognitive flexibility measured. One
      experimental approach to reduce global DA synthesis and transmission is through acute
      phenylalanine and tyrosine depletion (APTD). This dietary intervention involves the
      administration of an amino-acid mixture lacking in tyrosine and phenylalanine, which can be
      used to selectively lower DA synthesis in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive flexibility performance</measure>
    <time_frame>Measured over 5 hours four times.1st measurement taken at baseline (i.e. time 0). 2nd measurement taken 120 minutes after measurement 1. 3rd measurement taken 220 minutes after measurement 1. 4th measurement taken 270 minutes after measurement 1.</time_frame>
    <description>Measured using Wisconsin Card Sorting Test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cognitive flexibility performance</measure>
    <time_frame>Measured over 5 hours. 1st measurement taken at baseline (i.e. time 0). 2nd measurement taken 120 minutes after measurement 1. 3rd measurement taken 220 minutes after measurement 1. 4th measurement taken 270 minutes after measurement 1.</time_frame>
    <description>Measured using Probabilistic Reversal Learning</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cognitive Flexibility</condition>
  <arm_group>
    <arm_group_label>tDCS sham + balanced drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS sham + tyrosine depleted drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS anodal + balanced drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS anodal +tyrosine depleted drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sham tDCS and tyrosine depleted drink</intervention_name>
    <description>Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.</description>
    <arm_group_label>tDCS sham + tyrosine depleted drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Anodal tDCS and tyrosine depleted drink</intervention_name>
    <description>Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.</description>
    <arm_group_label>tDCS anodal +tyrosine depleted drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sham tDCS and balanced drink</intervention_name>
    <description>Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.</description>
    <arm_group_label>tDCS sham + balanced drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Anodal tDCS and balanced drink</intervention_name>
    <description>Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.</description>
    <arm_group_label>tDCS anodal + balanced drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either male or female

          -  You are aged between 18 and 30 years

          -  You are in good health

          -  You agree to fast overnight prior to testing

        Exclusion Criteria:

          -  Are suffering from cardiac, hepatic, renal, or neurological disorders

          -  Damaged or diseased skin on your face and scalp, or a sensitive scalp

          -  A history of alcohol or drug addiction, or severe psychiatric illness

          -  Are in drug treatment which may lower seizure threshold (i.e. epilepsy)

          -  You are pregnant

          -  Slept less than 6 hours prior to coming to the lab

          -  Suffer from phenylketonuria

          -  A history of or current experience of migraine or headaches

          -  A history of or current use of antidepressants

          -  A history of or current use of tyrosine supplements

          -  Consume more than five beverages containing caffeine per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychology labs</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03462303/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

